R&D Day Breakfast: Why C5a - Terminal Complement Target Deep Dive
A KOL Perspective on Hidradenitis Suppurativa and First Clinical Experience with IFX-1
Hosted by InflaRx N.V. (Nasdaq: IFRX)
The InflaRx founders, Prof. Niels Riedemann and Prof. Renfeng Guo and the InflaRx management team will share their in-depth complement research experience and address new insight and common misperception in terminal complement activation mechanisms, their choice of the key target C5a over its receptors and the development of InflaRx's breakthrough anti-C5a monoclonal antibody technology including its lead drug IFX-1. In addition, the team will provide an update on the current IFX-1 clinical phase II development in HS and speak to other C5a mediated disease opportunities.
The key opinion leader Professor Evangelos Giamarellos-Bourboulis, MD, PhD, (ATTIKON University Hospital – Athens, Greece), will discuss Hidradenitis Suppurativa (HS), a devastating auto-inflammatory skin disease with high unmet medical need. He will address the current treatment landscape and its limitations as well as its first-hand experience in treating HS patients with IFX-1. Dr. Giamarellos-Bourboulis will be available to answer questions at the conclusion of the event.
Friday, September 7, 2018
7:45-9:30 am EDT
Lotte New York Palace
455 Madison Ave
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.
Evangelos Giamarellos-Bourboulis, MD, PhD is Professor of Internal Medicine in the 4th Department of Internal Medicine at ATTIKON University Hospital in Greece. He leads one of the worldwide largest Hidradenitis Suppurativa (HS) outpatient clinics and was critically involved in the development of the first approved therapy in HS. Throughout the years he has advanced the field of HS therapy through an increasing amount of research related to the pathophysiology of the disease. Dr. Giamarellos-Bourboulis has conducted numerous investigator and sponsor initiated clinical trials in HS and is internationally recognized for his strong commitment in this field. Besides the HS field, Dr. Giamarellos-Bourboulis is an expert in research and clinical trials in the fields of immunology and severe infections and member of the Steering Committee of the World Sepsis Day. He was awarded in 2009 the ESCMID (European Society of Clinical Microbiology and Infectious Diseases) Young Investigator Research Award for his contribution in the immunotherapy of sepsis. He is chairing the Hellenic Sepsis Study Group and the Hellenic Sepsis Study Institute. He is the President-Elect of the European Shock Society. He has published over 350 research and review articles with more than 10,000 citations.